Login to Your Account

Prime Time for Five Prime in IPO Filing

By Marie Powers
Staff Writer

Monday, July 29, 2013
Protein and antibody drug developer Five Prime Therapeutics Inc. became the newest member of the class of 2013 biotech initial public offerings (IPOs) by filing an S-1 seeking to raise up to $60 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription